Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

these risks and uncertainties, which include, without limitation, risks related to Sunesis' need for additional funding, the risk that Sunesis' development activities for voreloxin, including enrollment and reporting of results, could be halted significantly or delayed for various reasons; the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval; the risk that preliminary data and trends may not be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; and risks related to the conduct of Sunesis' clinical trials and manufacturing. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

    Contacts:                                Media Contact:
    Sunesis Pharmaceuticals, Inc.            Invigorate Communications
    Eric Bjerkholt                           Monique Greer
    650-266-3717                             415-946-1075


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... Mich. , Jan. 15, 2014 As health officials ... flu virus, select Meijer pharmacies in Michigan ... throat to eligible patients, enabling Meijer pharmacists to administer tests ... protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July ... sensor for people with diabetes is being developed to measure ... researchers report. Scientists at Brown University in Providence, R.I., ... It uses light, metal and a special enzyme that changes ... diabetics have to prick their fingers to draw blood to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, ... retailer, has unveiled its new range of gorgeous ... current market, the demand for elegant Quinceanera outfits ... more beautiful items. All the company’s newly released ... trends. They are all elegant and vivid. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they will ... Senior Living Community in Palatine, IL. The group, called “New ... Wednesdays of every month. This group will begin on ... 55 S. Greeley St. Palatine, IL 60067. It is ... for the group. , “A grief support group is ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... cholesterol higher than national guidelines recommend that, if managed, ... a study published in the issue of Neurology, the ... ,The study of 1,040 people hospitalized for ... percent had cholesterol higher than recommended by national guidelines. ...
... the risk of becoming infected with tuberculosis (TB) and ... according to an analysis of previously published in issue ... the world’s population is infected with the bacteria that ... inactive by the immune system, according to background information ...
... Phase 3 study of the drug Vandetanib, marketed by London ... study will cover 508 patients of lung cancer in whom ... countries and 20 sites. , The patients who ... non-small cell lung cancer will be given the once-daily drug ...
... Ruby has been diagnosed with a brain tumor which is at ... led her parents// to approach the doctor who after routine tests ... The doctors have given her three to six months of life ... week course of radiation which is expected to reduce the size ...
... be able to provide ‘safe prawns’ for seafood allergy ... these prawns without the fear of an adverse reaction. ... removing from prawns the proteins that cause an allergic ... in Chemistry & Industry, the magazine of the SCI. ...
... infections such as pneumonia and acute bronchitis, says a ... of hospitalisation. ,Rhinoviruses are among the ... least 50 percent of all common colds. ... illnesses in children is increasingly accepted and has been ...
Cached Medicine News:Health News:Cholesterol in Stroke Patients Exceeds National Guidelines 2Health News:Susceptibility to TB is High Among the Smokers 2Health News:Common Cold may Cause Severe Respiratory Infection 2
... With the ProtecPoint Exit Alerting System, ... staff) and assets (e.g. medical equipment), ... your facility. With this form of ... cost savings, operating efficiencies, and overall ...
... Context-sensitive medicine is the ability of medical ... pre-determined ways based on what is happening ... associations a Radianse indoor positioning solution (IPS) ... it requires identity, location and time to ...
... the movement of controlled substances, critical ... done. VerdaSee's "intellishelvess" are designed to ... is possible with no human intervention. ... this possible. VerdaSee Intellishelf™ product solutions ...
Agility has delivered a RFID-enabled mobile asset management program....
Medicine Products: